Actively Recruiting
Edaravone in the Treatment of Optic Neuritis
Led by First Affiliated Hospital of Guangxi Medical University · Updated on 2025-02-27
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the effects of edaravone in treating patients with optic neuritis who are positive for aquaporin-4 antibodies. The study is based on previous findings where edaravone showed benefits in promoting remyelination and protecting nerve fibers in animals with neuromyelitis optica spectrum disorder (NMOSD). The goal is to evaluate whether edaravone can improve visual outcomes in affected patients. Participants in this study will receive edaravone injections at a dose of 30 mg three times a day. The study focuses on patients experiencing their first episode of optic neuritis within 30 days before starting treatment. The trial follows patients for 18 months to assess visual acuity and retinal nerve layer changes. There are no placebo or masking elements mentioned. During the study, researchers will monitor best-corrected visual acuity along with structural measurements of the retinal layers, including the ganglion cell-inner plexiform layer and the peripapillary retinal nerve fiber layer. These assessments will help determine the impact of edaravone on vision and retinal health. The total participation period extends to 18 months, throughout which patients will undergo regular evaluations to track treatment effects and safety.
CONDITIONS
Brief Title
Edaravone in the Treatment of Optic Neuritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Chinese patients aged 18 years or older with anti-aquaporin-4 antibody-positive optic neuritis
- Patients experiencing their first episode of optic neuritis in either eye
- First symptoms of optic neuritis occurred within 30 days before starting edaravone treatment
You will not qualify if you...
- Myopia greater than 6 diopters
- Presence of refractive media opacity that affects assessment of retinal layers or visual acuity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 18 months
Participants receive Edaravone injections three times a day to treat optic neuritis.
Regular visits to monitor treatment progress and visual function
Trial Site Locations
Total: 1 location
1
Yi Du
Nanning, China, 530021
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here